Skip to main content
Top
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Brk expression may affect the differentiation status of breast cancer cells

Authors: AJ Harvey, CJ Pennington, DR Edwards, SA Eccles, MR Crompton

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

The breast tumour kinase Brk (PTK6) is found in over two-thirds of breast cancer cell lines and tumours but is not expressed in normal mammary cells. Brk has previously been shown to play a role in regulating proliferation in breast tumour cells [1]. However, in vivo, the site of Brk expression in normal tissues is restricted to nonproliferating cells that are undergoing terminal differentiation such as those in the gut or the skin [2, 3]. This led us to hypothesise that Brk expression in breast tumours could be reflective of a differentiation phenotype, especially as a previous study had shown that involucrin, a marker of terminal keratinocyte differentiation, was expressed in a subset of tumours [4]. We therefore examined involucrin expression in breast tumour cells lines and patient biopsy samples. In addition we investigated whether inducers of differentiation in keratinocytes such as prolonged culture in suspension or vitamin D3 treatment could also affect differentiation of breast tumour cells. …
Literature
1.
go back to reference Harvey AJ, Crompton MR: Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene. 2003, 22: 5006-5010. 10.1038/sj.onc.1206577.CrossRefPubMed Harvey AJ, Crompton MR: Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene. 2003, 22: 5006-5010. 10.1038/sj.onc.1206577.CrossRefPubMed
2.
go back to reference Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, Thomason A, Tyner AL: A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene. 1995, 10: 349-357.PubMed Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, Thomason A, Tyner AL: A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene. 1995, 10: 349-357.PubMed
3.
go back to reference Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM, Tyner AL: BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999, 5: 1767-1777.PubMed Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM, Tyner AL: BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999, 5: 1767-1777.PubMed
4.
go back to reference Tsuda H, Sakamaki C, Fukutomi T, Hirohashi S: Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites. Br J Cancer. 1997, 75: 1519-1524.CrossRefPubMedPubMedCentral Tsuda H, Sakamaki C, Fukutomi T, Hirohashi S: Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites. Br J Cancer. 1997, 75: 1519-1524.CrossRefPubMedPubMedCentral
Metadata
Title
Brk expression may affect the differentiation status of breast cancer cells
Authors
AJ Harvey
CJ Pennington
DR Edwards
SA Eccles
MR Crompton
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1960

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine